NEW YORK/PARIS, June 5, 2026 – Major pharmaceutical companies are accelerating investments in artificial intelligence, forging a wave of partnerships with AI specialists to speed up drug discovery, cut development costs and improve success rates in an industry long plagued by high failure rates and lengthy timelines.

The latest deal came on Friday when French drugmaker Sanofi SA and AI biotech Owkin announced a multi-year collaboration to develop next-generation AI-powered “biopharma agents” for end-to-end drug discovery and development. The agreement includes a five-year licence for Owkin’s K Pro AI Scientist platform, which combines multimodal patient data with specialised biological AI systems to support decisions from early discovery through clinical trials.
‍‍

‍The move deepens a relationship that began in 2021 with a €90 million strategic partnership focused on oncology target identification and patient-subgroup analysis, later expanded to immunology drug positioning.“Owkin will lead the end-to-end development of AI-driven biopharma agents built specifically for Sanofi,” the companies said in a joint statement. Owkin framed the work as aligning with its goal of achieving “Biological Artificial Superintelligence” to help automate some of pharma’s most complex R&D challenges.The Sanofi-Owkin pact is part of a broader industry shift. In the first half of 2026 alone, Big Pharma has struck dozens of platform-style AI deals, moving beyond one-off molecule hunts toward building AI infrastructure across discovery, clinical development and operations. In May, Bristol-Myers Squibb Co. signed a strategic agreement with Anthropic to deploy the Claude AI model as an enterprise-wide “shared intelligence platform” for more than 30,000 employees, covering research, clinical development, manufacturing, commercial and corporate functions.
‍

‍In April, Gilead Sciences Inc. expanded its multi-year collaboration with Tempus AI, gaining enterprise-wide access to the Lens AI platform and broader real-world data sets to advance its oncology pipeline.
‍

Other recent tie-ups include Eli Lilly’s partnerships with AI startups Chai Discovery, Noetik and Insilico Medicine (the latter with potential value up to $2.75 billion), Pfizer’s multi-year deal with Boltz for custom models in antibody and small-molecule design, and Takeda’s collaboration with Iambic Therapeutics worth more than $1.7 billion.
‍

Analysts say the flurry reflects a strategic pivot: traditional R&D remains expensive and slow, with AI promising to slash timelines by 40-50% in some cases and boost Phase 1 success rates. Pharma giants are also pouring capital into internal AI capabilities, including Lilly’s billion-dollar AI infrastructure push with NVIDIA.The trend has lifted shares in some players. Sanofi stock rose 1.33% to $44.97 in premarket trading on Friday.With the global AI-in-pharmaceuticals market projected to grow rapidly, more deals are expected as companies race to integrate agentic AI and multimodal data into core workflows. Industry conferences this year have been dominated by discussions on scaling these technologies from pilot to production.